Cannabis Law Report

APRIL 13, 2022

The Center Square) – Marijuana sales in Colorado continued a downward trend in February totaling $145 million, according to the state’s latest market data. New Report Format in 2022! The monthly reports are now replaced with two reports that have data from every month since 2014. Marijuana Sales Report, 2014 to Date.

Marijuana 52

Marijuana Data Retail Collective 52

Cannabis Law Report

MAY 10, 2022

11 May 2022. First academic study of national medicinal cannabis data. The first in-depth study of Australia’s medicinal cannabis program, which began in 2016, shows the drug is being increasingly prescribed for various conditions. Very few studies have also been done examining cannabis for the treatment of sleep disorders.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Canna Law Blog

DECEMBER 21, 2023

Sales fell (again) along with licensee numbers (for the first time) According to OLCC data , retail sales between January 1, 2023 and November 30, 2023 clocked in at $874 million. decrease from $994 million in 2022, which itself was the first calendar year cannabis sales contracted in Oregon. That tally would be a 4.1%

Hemp 89

Hemp Retail Compliance Compliance 89

Cannabis Law Report

MARCH 17, 2022

The Australian Criminal Intelligence Commission (ACIC) on Monday released the 15th report of its National Wastewater Drug Monitoring Program. tonnes of methylamphetamine, cocaine, MDMA and heroin was consumed in 2020-21, the fifth year of the Program. 15 March 2022. An estimated 15.7 The drop of approximately 4.7

Consumption 52

Consumption Programs Data Treatment 52

Cannabis Law Report

OCTOBER 22, 2021

Food and Drug Administration (“FDA”) standards have been initiated in preparation for human clinical studies, expected in early 2022; and. Cybin continues to demonstrate superior properties of its CYB003 and CYB004 programs as we progress toward first-in-human studies, expected in early 2022.

Research and Development 52

Research and Development Safety Media Data 52

Cannabis Law Report

JANUARY 4, 2022

Medical marijuana treatment centers like Gold Leaf are the only businesses currently authorized to cultivate, process, and dispense low-THC cannabis and medical marijuana in Florida. Expands Agrify’s Footprint to Lucrative and Fast-Growing Florida Cannabis Market. BILLERICA, Mass., BILLERICA, Mass., About Agrify TTK Solution.

Extraction 52

Extraction Cultivation Programs Data 52

Cannabis Law Report

JANUARY 24, 2022

Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. Dr. Tucker has successfully advanced several programs through clinical development and regulatory approval. CAMBRIDGE, Mass.–(BUSINESS Dr. Tucker. “I

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

JANUARY 12, 2022

Through the partnership, Maya’s Real World Evidence Platform will be one of the core services offered to the association’s members when it officially launches in Q4 of 2022. Through the right mix of regulation, technology, and data, both are equally achievable,” says NPA CEO Britt Rollins. ABOUT MAYA.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] Brian Schatz & Cory Booker to Acting Director Tabak and Commissioner Califf (May 11, 2022), [link]. [2] Defining Psychedelics.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

DECEMBER 2, 2021

These recommendations will be sent to the Oregon Health Authority (OHA) for consideration during formal rulemaking, with hearings scheduled from February 14 to February 25, 2022. Applicants must also authorize their training program to conduct a criminal background check. Conducting Psilocybin Integration (14 Hours).

Law 52

Law Programs Therapy Education 52

Cannabis Law Report

DECEMBER 6, 2021

–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the appointment of Jeff W. Jacobs, Ph.D. as Chief Scientific Officer (CSO). Dr. Jacobs, who most recently served as CSO of Ardelyx, Inc.,

Research and Development 52

Research and Development Supply Chain Clinical Trials Medicine 52

The Cannigma

AUGUST 5, 2022

Of the people who take antidepressants, 30% won’t respond to treatment. But what other options do people suffering from depression, particularly treatment-resistant depression, have? What is ketamine treatment? Ketamine treatment for depression may be one of the biggest leaps forward in mental healthcare in decades.

Treatment 138

Treatment Research and Development Therapy Digestion 138

Veriheal

AUGUST 9, 2023

Equally, 76% believed that addiction is preventable and treatable, underscoring the value of early intervention and treatment programs. In 2022 alone, over 100,000 individuals lost their lives to opioids, a sobering figure that amplifies the necessity of widespread naloxone accessibility and knowledge.

Education 98

Education Vaping Cannabis Consumption 98

Cannabis Law Report

APRIL 11, 2022

April 11, 2022 (GLOBE NEWSWIRE) — Agrify Corporation ( Nasdaq:AGFY ) (“Agrify” or the “Company”), the most innovative provider of advanced cultivation and extraction solutions for the cannabis industry, announced it has signed a definitive agreement for its Agrify Total Turn-Key Solution (“Agrify TTK Solution”) with Loud Wellness Inc. .

Extraction 52

Extraction Cultivation Environment Concentrates 52

Cannabis Law Report

JANUARY 9, 2022

Since 2014 when sales began in Colorado and Washington, legalization policies have provided states a new revenue stream to bolster budgets and fund important services and programs. Colorado has a robust medical program, with about 1.6% Legalizing cannabis for adults has been a wise investment. of the population enrolled.

Collective 52

Collective Policy Retail Programs 52

Freedom Leaf

OCTOBER 15, 2018

Frontier Data predicts total sales of all CBD products in the U.S. billion by 2022. Frontier Data predicts total sales of all CBD products in the U.S. billion by 2022. Legally, all CBD products in California must come through the regulated adult-use or medical programs. will top $1.9 John’s wort. will top $1.9

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

Cannabis Law Report

AUGUST 27, 2021

The Rules will be effective until at least August 19, 2022. The Rules also create a pathway for Alternative Treatment Centers (ATC) previously licensed under New Jersey’s medical cannabis law to expand their operations to include recreational cannabis. –> Scroll to see full table data. License Application Type.

Cultivation 105

Cultivation Conditions Business Cannabis 105

Project CBD

JUNE 20, 2023

Food and Drug Administration, three are prescribed for the treatment of chemotherapy-induced nausea and vomiting. As of March 2022, approximately 120,000 patients were registered in the program. But the most telling findings involve these patients’ perceptions of cannabis use as a treatment for IBD.

Cannabinoids 208

Cannabinoids Patients Treatment Conditions 208

Cannabis Law Report

DECEMBER 21, 2021

The rapid increase in the volume of enterprise data and growing automation of business processes across several end-use industries such as retail, manufacturing, healthcare, and transportation are expected to drive the demand for business software and services over the forecast period. billion in 2020 (Grandview Research). from 2021 to 2028.

Research and Development 52

Research and Development Supply Chain Data Business 52

Cannabis Law Report

AUGUST 4, 2021

We thus provide comparison with the pre-pandemic period of H1 2019 as an additional data point. At the time of FY 2020 results publication, we estimated that EUR 250m revenues had been lost in FY 2020 due to the impact of COVID-19 lockdowns and travel restrictions and the objective was to recover these revenues by 2022.

Business 105

Business Research and Development Environment Food 105

CannaTech

OCTOBER 14, 2018

The state was well-positioned to permit this type of farming back in 2013 when Senate Bill 566 was enacted, conditionally approving an industrial hemp pilot program. billion by 2022, according to New Frontier Data, a premier cannabis data analytics firm. In the U.S.

Hemp 53

Hemp Research and Development Agriculture Seed-To-Sale 53

Cannabis Law Report

JANUARY 20, 2022

Eleusis designed ELE-Psilo, a proprietary psilocybin-based drug candidate that is formulated for IV infusion and in development for the treatment of depression. Eleusis secured an Innovation Passport Designation for ELE-Psilo in adult treatment-resistant depression under the U.K. The combined company expects to receive up to $287.5

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

NOVEMBER 12, 2021

(Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced financial results for the first quarter of its fiscal year ending June 30, 2022 and reported recent business highlights. Condensed Balance Sheet Data. . .

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Veriheal

AUGUST 31, 2021

This year, we are happy to announce we are expanding our scholarship program and awarding $20,0000 in scholarships to 20 winners. . Major/Program: Business Management with a Minor in Cannabis Studies. Major/Program: Art. Major/Program: Business Administration. Major/Program: Nursing. Matthew Aaron Vogel .

Research and Development 116

Research and Development Supply Chain Programs Education 116

Veriheal

SEPTEMBER 14, 2021

The findings of a new study into cannabis use disorder (CUD) among veterans have been released by a team of researchers from Pennsylvania’s Center of Excellence in Substance Addiction Treatment and Education at the Corporal Michael J. Crescenz VA Medical Center. 3,000 Veterans Partook in Survey on CUD . Sponsored by Sen.

Consumption 97

Consumption Research and Development Treatment Programs 97

Cannabis Law Report

JUNE 7, 2021

Since 2014, when sales began in Colorado and Washington, legalization policies have provided states a new revenue stream to bolster budgets and fund important services and programs. Colorado has a robust medical program, with about 1.6% As of May 2021, states reported a combined total of $7.9 of the population enrolled.

Marijuana 91

Marijuana Retail Collective Programs 91

Cannabis Law Report

NOVEMBER 29, 2021

In short: IMO COMPASS Pathway is one of the most undervalued & impactful biotech stocks out there – and atai is committed to being the global leader in novel mental health treatments. We think the COMPASS Phase 2b trial for Treatment-Resistant Depression (TRD) is a total game-changer. Published on November 30, 2021. 18 articles.

Treatment 52

Treatment Clinical Trials Data Patients 52

Cannabis Law Report

DECEMBER 15, 2021

In 2021, atai has achieved many major milestones, for example the promising phase 2a data for its schizophrenia drug RL-007 or the Phase 2b readout of Compass Pathways , of which atai owns 22.6% As we move into 2022, 10 milestones are anticipated to happen within the existing pipeline alone. 4) Digital & Data.

Research and Development 52

Research and Development Data History Patients 52

Cannabis Law Report

NOVEMBER 26, 2021

Topline results are expected in Q1 2022. With the anticipated launch of Pfizer’s oral COVID-19 antiviral drug candidate, Can-Fite has made a strategic decision to end its COVID-19 program and to focus its resources on its other clinical programs, all in advanced clinical trials. Fortified Balance Sheet. Financial Results.

Clinical Trials 52

Clinical Trials Research and Development Treatment Data 52

Alchimia

JANUARY 25, 2022

At the beginning of this new year of 2022, a news story about how cannabis can help fight COVID-19 was picked up by many non-cannabis media. This study highlights CBD and its active metabolite, 7-OH-CBD, as potential preventive agents and therapeutic treatments for SARS-CoV-2 in the early stages of infection.

Research and Development 98

Research and Development Terpenes CBD Treatment 98

Kind Meds (Cannabis Education Blog)

FEBRUARY 7, 2022

As policies become more data-driven and progressive, cultivation and production technologies have continued to improve drastically over the past several years. Review our compilation of cannabis trends for 2022 to stay up to date on the latest news in the cannabis industry and ensure you are prepared for the future.

Recreational 52

Recreational Data Cannabis DEA 52

The Cannigma

FEBRUARY 1, 2023

Unlike healthy cells, these abnormal cells don’t die as they are typically programmed to do, and instead begin to grow and divide uncontrollably, effectively circumventing the body’s normal checks and balances. 7 The use of cannabis as a cancer treatment was popularized by Rick Simpson, a medical cannabis advocate.

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

The Blunt Truth

FEBRUARY 24, 2022

The legislation would expunge misdemeanor convictions and fund substance abuse treatment programs. Department of Agriculture released the first National Hemp Report, and it’s full of data on the industry. Demographics on growers, yield numbers by state, pricing data – all available here. supreme court. Stay tuned!

Decriminalization 111

Decriminalization Hemp Data Agriculture 111

Cannabis Law Report

NOVEMBER 15, 2021

“This is an exciting time at Virpax, and we believe that all of our product candidates have the potential to deliver significant improvements and benefits to currently existing treatment options,” concluded Mr. Mack. RECENT DEVELOPMENTS. On July 30, 2021, Virpax announced the appointment of Gerald W. Bruce and Michael F.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

SEPTEMBER 1, 2022

AUSTIN, Texas, August 31, 2022 –( BUSINESS WIRE )–As Pain Awareness Month begins, Texas Original is calling on Texas’ legislature to add chronic pain as a qualifying condition to the state’s Compassionate Use Program (CUP). 1 reason patients seek medical cannabis is to augment their pain management treatment.

Chronic Pain 52

Chronic Pain Programs Patients Conditions 52

Cannabis Law Report

AUGUST 31, 2022

AUSTIN, Texas–(BUSINESS WIRE)–As Pain Awareness Month begins, Texas Original is calling on Texas’ legislature to add chronic pain as a qualifying condition to the state’s Compassionate Use Program (CUP). 1 reason patients seek medical cannabis is to augment their pain management treatment. The data is clear.

Chronic Pain 52

Chronic Pain Programs Patients Conditions 52